Soluble CD163 from activated macrophages predicts mortality in acute liver failure
Soluble CD163 from activated macrophages predicts mortality in acute liver failure
复制标题
DOI：
10.1016/j.jhep.2007.05.014
复制
发表时间：
2007-11-01
影响因子：
25.7
通讯作者：
Lee, William M.
中科院分区：
文献类型：
--
作者：
Moller, Holger Jon;Gronbaek, Henning;Lee, William M.
背景/目的：可溶性CD163(SCD163)是巨噬细胞炎症激活过程中在血清中释放的一种清道夫受体。我们调查了sCD163是否升高并预测了急性肝功能衰竭(ALF)的预后。方法：从美国ALF研究组登记的100名连续患者中收集样本，在第1天和第3天获得血清，并前瞻性地获得临床数据。结果：ALF患者血清sCD163中位数为21.1 mg/I(3.6~74.9)，显著高于正常对照组(2.3 mg/I，0.65~5.6)和稳定期肝硬化组(9.8 mg/I，3.6~16.9，P=0.0002)。第1天的sCD163与ALT、AST、胆红素、肌酐显著相关。死亡患者第3天血清sCD163浓度较自然存活者升高，分别为29.0 mg/I(7.2~54.0)和14.6 mg/I(3.5~67.2)(p=0.0025)。接受移植的患者处于中等水平。以26 mg/l为界值，其敏感性和特异性分别为62%和81%。结论：活化的巨噬细胞参与了ALF的发生，导致sCD163水平升高10倍。高水平的sCD163(26 mg/I)与死亡结局显著相关，并可与其他指标一起用于判断预后。(C)2007年欧洲肝脏研究协会。爱思唯尔出版，版权所有。
Background/Aims: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF).Methods: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA.Results: The median level of sCD163 was significantly increased in ALF (21.1 mg/I (range 3.6-74.9)) as compared to healthy controls (2.3 mg/I (0.65-5.6), p < 0.0001) and patients with stable liver cirrhosis (9.8 mg/I (3.6-16.9), p = 0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0 mg/I (7.2-54.0) vs. 14.6 mg/I (3.5-67.2), respectively (p = 0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26 mg/I was 62% and 81%, respectively.Conclusions: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (> 26 mg/I) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis. (c) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.